Retrieve available abstracts of 54 articles: HTML format
Single Articles
July 2025
OU G, Gou J, Ou H, Zheng H, et al Gut markers for metastatic melanoma receiving immunotherapy.
BMC Cancer. 2025;25:1083. PubMedAbstract available
May 2025
LUCKETT T, Ng CA, Lai-Kwon J, Kee D, et al Uncertainty and hope in people with metastatic uveal melanoma in the era of
immunotherapy and targeted treatments: a theory-based qualitative study.
BMC Cancer. 2025;25:939. PubMedAbstract available
CHEN SH, Yu BY, Kuo WY, Lin YB, et al Unveiling the immune microenvironment of complex tissues and tumors in
transcriptomics through a deconvolution approach.
BMC Cancer. 2025;25. PubMedAbstract available
April 2025
YE M, Ren S, Luo H, Wu X, et al Integration of graph neural networks and transcriptomics analysis identify key
pathways and gene signature for immunotherapy response and prognosis of skin
melanoma.
BMC Cancer. 2025;25:648. PubMedAbstract available
ZHAO S, Li Z, Liu K, Wang G, et al Combining multi-omics analysis with machine learning to uncover novel molecular
subtypes, prognostic markers, and insights into immunotherapy for melanoma.
BMC Cancer. 2025;25:630. PubMedAbstract available
ZHAO W, Chen Z, Fu W, Ye C, et al Induction of apoptosis and hypoxic stress in malignant melanoma cells via
graphene-mediated far-infrared radiation.
BMC Cancer. 2025;25:620. PubMedAbstract available
March 2025
MANGER I, Schmitt C, Berking C, French LE, et al Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint
inhibitor therapy in melanoma patients: a retrospective cohort study.
BMC Cancer. 2025;25:565. PubMedAbstract available
MOLONEY M, Harris PM, Kaczmarski P, Zheng S, et al Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients
treated with high resolution dermal ultrasound-guided superficial radiotherapy, a
multi-institutional study.
BMC Cancer. 2025;25:526. PubMedAbstract available
January 2025
ZHOU L, Zhou Q, Guo Q, Lai P, et al Dual role of Cathepsin S in cutaneous melanoma: insights from mendelian
randomization and bioinformatics analysis.
BMC Cancer. 2025;25:104. PubMedAbstract available
NASERI H, Safaei AA Diagnosis and prognosis of melanoma from dermoscopy images using machine learning
and deep learning: a systematic literature review.
BMC Cancer. 2025;25:75. PubMedAbstract available
EVERATT R, Kuzmickiene I, Brasiuniene B, Vincerzevskiene I, et al Postdiagnostic use of antihypertensive medications and survival in colorectal,
lung, corpus uteri, melanoma and kidney cancer patients with hypertension.
BMC Cancer. 2025;25:38. PubMedAbstract available
December 2024
BORILOVA S, Grell P, Selingerova I, Gescheidtova L, et al Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors
in patients with advanced malignant melanoma and non-small cell lung cancer.
BMC Cancer. 2024;24:1590. PubMedAbstract available
FARIAS RM, Jiang Y, Levy EJ, Hwang C, et al Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary
intervention study in patients with melanoma receiving immunotherapy.
BMC Cancer. 2024;24:1493. PubMedAbstract available
November 2024
ZHANG S, Zang L, Li Y, Pang Y, et al Numb and NumbL inhibit melanoma tumor growth by influencing the immune
microenvironment.
BMC Cancer. 2024;24:1419. PubMedAbstract available
CAI X, Lin J, Li C, Xu T, et al MET amplification correlates with poor prognosis and immunotherapy response as a
subtype of melanoma: a multicenter retrospective study.
BMC Cancer. 2024;24:1384. PubMedAbstract available
October 2024
FERRIER ST, Li M, Burnier JV Azacytidine treatment affects the methylation pattern of genomic and cell-free
DNA in uveal melanoma cell lines.
BMC Cancer. 2024;24:1299. PubMedAbstract available
DI PIETRO FR, Marinelli D, Verkhovskaia S, Poti G, et al Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients
resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
BMC Cancer. 2024;24:1220. PubMedAbstract available
August 2024
YU H, Ding G, Gong Q, Ma J, et al Modulation of PD-L1 by Astragalus polysaccharide attenuates the induction of
melanoma stem cell properties and overcomes immune evasion.
BMC Cancer. 2024;24:1034. PubMedAbstract available
July 2024
GARCIA AM, Parra-Lara LG, Mendoza-Urbano DM, Bravo JC, et al Survival of patients with mucosal melanoma in Cali, Colombia: a retrospective
cohort study.
BMC Cancer. 2024;24:886. PubMedAbstract available
YIN W, Li R, Zhang Z, Wang Y, et al Causal association between skin cancer and immune cells: mendelian randomization
(MR) study.
BMC Cancer. 2024;24:849. PubMedAbstract available
TONDER JE, Bonnelykke-Behrndtz ML, Laurberg T, Rossell EL, et al Melanoma risk, tumour stage, and melanoma-specific mortality in individuals with
diabetes: a systematic review and meta-analysis.
BMC Cancer. 2024;24:812. PubMedAbstract available
DIDIER AJ, Nandwani SV, Watkins D, Fahoury AM, et al Patterns and trends in melanoma mortality in the United States, 1999-2020.
BMC Cancer. 2024;24:790. PubMedAbstract available
June 2024
GAULT A, Hogarth L, Williams KC, Greystoke A, et al Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN
(MEDALLION): protocol for an observational cancer immunotherapy cohort study.
BMC Cancer. 2024;24:733. PubMedAbstract available
May 2024
KAMMINGA NCW, van der Veldt AAM, Wakkee M, van den Berge FR, et al From decision to reflection: understanding the experiences and unmet care needs
of patients treated with immunotherapy for melanoma in the adjuvant or metastatic
setting.
BMC Cancer. 2024;24:662. PubMedAbstract available
CHRISTAKOUDI S, Tsilidis KK, Riboli E Prospective associations of leucocyte subtypes and obesity with the risk of
developing cutaneous malignant melanoma in the UK Biobank cohort.
BMC Cancer. 2024;24:625. PubMedAbstract available
JANSSEN JC, van Dijk B, de Joode K, Aarts MJB, et al Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a
complete or partial response in patients with irresectable stage III or
metastatic melanoma treated with first-line ipilimumab-nivolumab - study
protocol.
BMC Cancer. 2024;24:632. PubMedAbstract available
MIAO L, Miao T, Zhang Y, Hao J, et al Association of lipid-lowering drug targets with risk of cutaneous melanoma: a
mendelian randomization study.
BMC Cancer. 2024;24:602. PubMedAbstract available
April 2024
ZHANG Y, Zheng J, Chen M, Zhao S, et al Modulating DNA damage response in uveal melanoma through embryonic stem cell
microenvironment.
BMC Cancer. 2024;24:519. PubMedAbstract available
SHENG M, Sun R, Fu J, Lu G, et al The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary
metastasis.
BMC Cancer. 2024;24:399. PubMedAbstract available
March 2024
WHITMAN ED, Totev TI, Jiang S, da Costa WL Jr, et al Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of
treatment choice in stage III cutaneous melanoma in the US.
BMC Cancer. 2024;24:389. PubMedAbstract available
NEVAKIVI R, Siiskonen H, Haimakainen S, Harvima IT, et al Spectrum of malignant and premalignant skin lesions in 505 adult subjects at risk
of skin cancers.
BMC Cancer. 2024;24:338. PubMedAbstract available
February 2024
ZHU Z, Wang W, Zha Y, Wang X, et al Development and validation of a nomogram for predicting overall survival in
patients with sinonasal mucosal melanoma.
BMC Cancer. 2024;24:184. PubMedAbstract available
January 2024
SAAMARTHY K, Ahlqvist K, Daams R, Balagunaseelan N, et al Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression
in melanoma cells.
BMC Cancer. 2024;24:103. PubMedAbstract available
WANG X, Li J, Li Y, Lv M, et al Single-cell analysis of the cellular landscape of vulvar melanoma provides new
insight for immunotherapy administration.
BMC Cancer. 2024;24:101. PubMedAbstract available
November 2023
TSAKMAKLIS A, Farowski F, Zenner R, Lesker TR, et al TIGIT(+) NK cells in combination with specific gut microbiota features predict
response to checkpoint inhibitor therapy in melanoma patients.
BMC Cancer. 2023;23:1160. PubMedAbstract available
ZHAO Y, Amorrortu RP, Stewart SC, Ghia KM, et al Melanoma and CLL co-occurrence and survival: role of KC history.
BMC Cancer. 2023;23:1084. PubMedAbstract available
October 2023
LI L, Pei B, Feng Y Exogenous hormone therapy and non-melanoma skin cancer (keratinocyte carcinoma)
risk in women: a systematic review and meta-analysis.
BMC Cancer. 2023;23:946. PubMedAbstract available
September 2023
JOSHY G, Khalatbari-Soltani S, Soga K, Butow P, et al Pain and its interference with daily living in relation to cancer: a comparative
population-based study of 16,053 cancer survivors and 106,345 people without
cancer.
BMC Cancer. 2023;23:774. PubMedAbstract available
August 2023
LIU J, Luo B, Zhang P, Jiang K, et al Necroptosis-related LncRNAs in skin cutaneous melanoma: evaluating prognosis,
predicting immunity, and guiding therapy.
BMC Cancer. 2023;23:752. PubMedAbstract available
July 2023
OLATEJU OA, Zeng Z, Thornton JD, Mgbere O, et al Management of metastatic melanoma in Texas: disparities in the utilization of
immunotherapy following the regulatory approval of immune checkpoint inhibitors.
BMC Cancer. 2023;23:655. PubMedAbstract available
June 2023
LIU W, Ji Y, Wang F, Li C, et al Morusin shows potent antitumor activity for melanoma through apoptosis induction
and proliferation inhibition.
BMC Cancer. 2023;23:602. PubMedAbstract available
GEOFFROIS L, Harle A, Sahki N, Sikanja A, et al Personalized follow-up of circulating DNA in resected stage III/IV melanoma:
PERCIMEL multicentric prospective study protocol.
BMC Cancer. 2023;23:554. PubMedAbstract available
LI H, Sun X, Zhao Y, Zhang C, et al Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for
tumor prognosis and immunotherapy response prediction.
BMC Cancer. 2023;23:528. PubMedAbstract available
May 2023
DIETSCH B, Weller C, Sticht C, de la Torre C, et al Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and
metastatic pattern.
BMC Cancer. 2023;23:436. PubMedAbstract available
WU N, Sun H, Sun Q, Zhang F, et al Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review
and meta-analysis.
BMC Cancer. 2023;23:414. PubMedAbstract available
GRAVIS G, Marino P, Olive D, Penault-LLorca F, et al A non-inferiority randomized phase III trial of standard immunotherapy by
checkpoint inhibitors vs. reduced dose intensity in responding patients with
metastatic cancer: the MOIO protocol study.
BMC Cancer. 2023;23:393. PubMedAbstract available
LIU J, Pei S, Zhang P, Jiang K, et al Liquid-liquid phase separation throws novel insights into treatment strategies
for skin cutaneous melanoma.
BMC Cancer. 2023;23:388. PubMedAbstract available
April 2023
TANG W, Shao Q, He Z, Zhang X, et al Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney
renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer
Analysis.
BMC Cancer. 2023;23:303. PubMedAbstract available
REZAIE Y, Fattahi F, Mashinchi B, Kamyab Hesari K, et al High expression of Talin-1 is associated with tumor progression and recurrence in
melanoma skin cancer patients.
BMC Cancer. 2023;23:302. PubMedAbstract available
March 2023
SUN S, Deng M, Wen J, Chen X, et al Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated
with immune infiltration in skin cutaneous melanoma.
BMC Cancer. 2023;23:292. PubMedAbstract available
KAMMINGA NCW, Wakkee M, De Bruin RJ, van der Veldt AAM, et al Oncological healthcare providers' perspectives on appropriate melanoma
survivorship care: a qualitative focus group study.
BMC Cancer. 2023;23:278. PubMedAbstract available
HERRSPIEGEL C, Plastino F, Lardner E, Seregard S, et al A serum protein signature at the time of Uveal Melanoma diagnosis predicts
long-term patient survival.
BMC Cancer. 2023;23:277. PubMedAbstract available
JOHNSON DB, Atkins MB, Hennessy C, Wise-Draper T, et al Impact of COVID-19 in patients on active melanoma therapy and with history of
melanoma.
BMC Cancer. 2023;23:265. PubMedAbstract available
SHEN Y, Li M, Liao L, Gao S, et al Plasma exosome-derived connexin43 as a promising biomarker for melanoma patients.
BMC Cancer. 2023;23:242. PubMedAbstract available